Leading the way.
Thriving on an open and transparent operating style, we are led by a highly experienced senior team and a world-renowned Scientific Advisory Board.
Management Team
Robert E. Fallon
President & CEO
Mr. Fallon is President, CEO and co-Founder of Phosplatin Therapeutics. He is a highly respected leader with decades of global transactional and strategic leadership. He is former Chairman & CEO of The Korea Exchange Bank, a large publicly traded company, and prior to that he ran all of Asia-Pacific for JP Morgan Chase.
He holds a BA in Mathematics from Ohio University, and an MBA from Harvard Business School. Mr. Fallon also serves as chairman of The Council on International Educational Exchange (CIEE), and is a member of The Council on Foreign Relations.
Matthew R. Price
Executive Vice President & COO
Mr. Price is Executive Vice President, Chief Operating Officer and co-Founder of Phosplatin Therapeutics, and is responsible for strategy, finance and operations across the company's activities, which have expanded to sixteen countries since inception. He helped negotiate the original license for the company's PT-112 development program, and currently oversees the clinical and translational research and development involving phase I / II studies in solid tumors and hematological malignancies. He is also responsible for the company's sub-license collaboration with SciClone Pharmaceuticals for greater China. In addition, he led the design and launch of the clinical trials collaboration jointly with Pfizer and Merck KGaA, Darmstadt, Germany.
He holds an AB from Princeton University, graduating summa cum laude and Phi Beta Kappa. He previously held research and managerial roles in the NGO and non-profit sectors working in the US and Germany. He earned an MBA from Columbia Business School, where he was a Chazen Society Fellow in International Business.
Joseph O’Donnell, MD
Chief Medical Officer
Dr. O’Donnell joins the Phosplatin Therapeutics team as interim Chief Medical Officer. As a member of the senior leadership, he is responsible for oversight of all clinical strategy and operations, safety monitoring, and collaboration with clinical sites and industry partners on alliances and strategic initiatives.
Dr. O’Donnell comes to the Company from the Geisel School of Medicine at Dartmouth, where he was an Associate Dean at the medical school and senior scholar at the C. Everett Koop Institute, and held the Elizabeth DeCamp McInerney endowed chair as a Professor of Medicine and Psychiatry. He was chief of oncology at the Dartmouth affiliated White River Junction VA Hospital, and a member and former associate director of the Norris Cotton Cancer Center. He has had extensive experience in clinical oncology, especially involving the cancers of most interest to Phosplatin Therapeutics, and has extensive clinical trials experience with CALGB, RTOG, VA Cooperative Studies and locally initiated Dartmouth protocols. He is past president of the American Association for Cancer Education, past editor of its Journal of Cancer Education and recipient of its highest award, the Margaret Hay Edwards Medal for achievement in cancer education. Joe previously served on the Company’s Scientific Advisory Board since inception.
He graduated with an A.B. in biology summa cum laude from Harvard College and an MD from Harvard Medical School. He did his internal medicine training at Dartmouth and his oncology training as a clinical associate at the National Cancer Institute. He is board certified in Internal Medicine and Medical Oncology.
Tyler Ames, PhD
Senior Vice President, Research & Development
Dr. Ames is Senior Vice President of Research & Development at Phosplatin Therapeutics, and leads the company's translational research efforts globally across multiple institutions.
Dr. Ames received his BS with high distinction in Biology and Biotechnology from Worcester Polytechnic Institute, and earned his doctorate in Molecular, Cellular and Developmental Biology from Yale University, where he focused on Nucleic Acid Biochemistry. Most recently he was a post-doctoral fellow at University of California Berkeley, focusing on Commercial Applications of Yeast Genetics.
Brooke Raphael, MS
Vice President, Strategy & Operations
Ms. Raphael is Vice President of Strategy & Operations, responsible for oversight and development of Phosplatin’s strategic commercial plan. She previously worked at Intercept Pharmaceuticals where she was the Chief of Staff to the President of US Commercial, and was a member of the Strategic Marketing team. Prior to that, she worked at Celgene in a variety of roles, including program management for early development, marketing for Revlimid®, and early commercialization at Celgene Cellular Therapeutics.
She graduated summa cum laude from Tufts University with a dual major in Civil and Biomedical Engineering, received her MS in Biomedical Engineering from Columbia University, and also earned her MBA from Columbia Business School.
Frances Bonham
Vice President, Finance & Administration
Ms. Bonham is Vice President of Finance & Administration at Phosplatin Therapeutics, responsible for financial management and operational support of the company’s initiatives. She has more than 25 years of experience in the financial services industry, where she was a managing director at JP Morgan Chase, responsible for covering international clients. Most recently she worked in external affairs at the Korea Society in New York.
She earned her Bachelors' degree from the University of Michigan and her MBA from the Thunderbird Graduate School of Global Management.
Development Collaborators
Martin A. Graham, PhD
Pharmacokinetics
Dr. Graham has been involved in drug development for over 25 years and is a specialist in PK /PD analysis, and serves as Lead Pharmacokineticist for Phosplatin Therapeutics' drug development efforts. He began his career at Sanofi-Synthelabo, in both the UK and the US. Dr. Graham later served as Director of Pharmacokinetics at Centocor Corporation, a Johnson and Johnson Company; VP of Research and Development at Gemin X Biotechnologies; and VP of Development and Regulatory Affairs at Tetralogic Pharmaceuticals.
He founded PKPD Bioscience in 2004, which was later integrated into Kinderpharm, a pediatric drug development company he had also founded in 2014. Dr. Graham serves as President & CEO of both entities. With his extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA, Dr. Graham has been involved in numerous regulatory filings in the US, Japan and Europe for a wide variety of products including Oxaliplatin, Rasburicase, Mitoguazone, Tirapazamine, Alfuzosin, Birinapant, Stelara and Remicade.
He is a graduate of Leeds University, England where he earned his BSc in Pharmacology and Microbiology, and went on to earn his PhD from the University of London at the Institute of Cancer Research, Royal Marsden Hospital in 1990. He is the author of a text book on the pharmacokinetics of cancer chemotherapy and has substantial publication record in the area of pharmacokinetics, drug metabolism and clinical pharmacology.
Michael H. Silverman, MD, FACP
Clinical Development
Dr. Silverman is a board-certified internist with over 25 years of experience in biopharmaceutical industry clinical research, product development, and strategic planning. He has served Phosplatin Therapeutics in its clinical development matters since inception. His pharmaceutical industry career has included positions of increasing responsibility at both global and start-up companies, where he has managed multiple pharmaceutical and biotechnology projects across a broad scope of therapeutic areas. He is currently President of Biostrategics Consulting, Ltd.
Prior to beginning his consulting activities, among other roles Dr. Silverman served as manager, KPMG Healthcare Consulting; Vice President of Clinical Research at Biopure Corporation in Cambridge, MA; and director of clinical research at Sandoz Research Institute in East Hanover, NJ. He was in clinical practice of medicine for seven years. Dr. Silverman received his BS from the University of Illinois and his MD from the University of Chicago.
Thomas Eckrich, PhD
CMC Regulatory Affairs
Dr. Eckrich is an experienced Chemistry Manufacturing and Controls (CMC) executive with 33 years of experience in the pharmaceutical industry, primarily with Eli Lilly and Company. His accomplishments include NDA submissions for Loracarbef, Gemcitabine, Raloxifene and Tadalafil. He also managed Eli Lilly’s European development center in Mont Saint Guibert, Belgium, leading the growth of the premier small molecule process R&D group in the US pharma industry during the early 2000s, and established a network of more than 30 company relationships for Lilly’s development outsourcing capability.
In 2014, Dr. Eckrich founded Eckrich consulting services, LLC, which provides expertise to the chemical and pharmaceutical industries in chemical process development and manufacturing, with a focus on synthetic organic chemistry. Dr. Eckrich earned a doctorate in Chemistry from Harvard University in 1984, studying with Professor E. J. Corey, the 1990 Nobel Laureate in Chemistry.
Scientific Advisory Board
Daniel D. Von Hoff, MD FACP
Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and Medical Director of Research at McKesson Specialty Health, US Oncology Research. He is also Professor of Medicine, Mayo Clinic Scottsdale, AZ.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.
Dr. Von Hoff has published more than 675 papers, 140 book chapters and over 1170 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was also a Founder of Ilex Oncology, which obtained FDA approval for two new anti-cancer agents: Campath for the treatment of patients with CLL and multiple sclerosis; and Clofarabine for the treatment of children with Leukemia. The company was acquired by Genzyme.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Daniel D. Karp, MD
Dr. Karp graduated from Harvard College in 1969, and received his medical degree from the Duke University School of Medicine in 1973. He was awarded numerous postgraduate and clinical fellowships, including at the Sidney Farber Cancer Institute in Boston from 1978-80. Dr. Karp’s focus at MD Anderson Cancer Center is on new drug development in the phase I facility, as well as medical graphics and informatics, and cancer chemoprevention.
Dr. Karp is proud to have had a role in the early clinical trials of Epirubicin, the Taxanes, and the new Targeted Oral Inhibitors of the Epidermal and Vascular Growth Factor Receptors, as well as in recent studies of the Insulin Growth Factor Receptor (IGFR).
J. Kay Noel, PhD
Dr. Noel has had thirty years of experience in pharmaceutical drug development. She currently serves as Chief Operating Officer of Collaborative Medicinal Development, a privately held drug development group focused on neuro-degenerative diseases. She was previously Co-founder and COO of OncoEthix SA, which was sold to Merck in 2014, and before that was Co-Founder and VP of Business Development of Oncology Therapeutics Network, which was sold to Bristol Myers Squibb.
Earlier in her career she was director of Biologics R&D at Abbott. Dr. Noel holds a PhD in Biophysics from the University of Michigan, and completed post-doctoral studies at UCLA under a fellowship from the National Institutes of Health.
Jose Jimeno, MD, PhD
Dr. Jimeno is a seasoned medical oncologist, who also holds a PhD from the University of Barcelona. He has had a focus in drug development for over twenty years. Dr. Jimeno served as Chief Medical Officer at Phosplatin Therapeutics, in which role he was instrumental in the early clinical development of PT-112, and joins the Scientific Advisory Board in order to maintain his involvement in the program. He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for the integrated development of Yondelis®, which is approved in the US, the EU, Japan, and more than 60 other countries for the treatment of ovarian cancer and sarcoma; the development of Aplidine® in advanced cancer patients; and the design of the pivotal study in multiple myeloma, which has had its first approval in Australia.
His prior industry roles include work at Farmitalia Carlo Erba and US Biosciences, where he focused on novel compounds in the anthracycline and anti-metabolite therapeutic classes. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company focused on personalized medicine, where he was involved in the development of the EGFR mutation diagnostic approved by the FDA for use in non-small cell lung cancer (NSCLC) cancer patients. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.
Lucas A. de Breed, PhD
Dr. Lucas de Breed is the Founder and Managing Director of August Care (AUGC), a tech-enabled financial services company focused on effective market adoption of high-cost precision medicine.
Dr. de Breed has over a decade of international experience in all phases of drug development and commercialization and a strong financial background. Previously as a Manager at Deallus, a global strategy consulting firm for Top 30 Pharma clients, he led the oncology business unit and founded the firm’s East Coast office. As an Investment Director at INKEF Capital, a leading European VC firm, he invested $60 million in US and European therapeutics start-ups in the fields of oncology, audiology, fibrosis, neuromuscular disorders, metabolic diseases, and monogenetic rare diseases, and served on the respective Boards. At INKEF, he was involved in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million.
Dr. de Breed holds a PhD from University College London and an MBA from Stanford University. He has also co-authored several scientific papers. He is a director at Quantum Leap Healthcare, and also serves on the Advisory Board of FIRST, an early stage investment fund for cardiovascular and regenerative medicine
Board of Directors
Robert E. Fallon, Chairman
Mr. Fallon is Chairman of the Board of Directors. He is a co-founder of Phosplatin Therapeutics and serves as President & CEO.
John B. Caouette, Vice Chairman
Mr. Caouette is Founding Chairman of Channel Capital, which provides technology-enabled financing to corporates operating in global markets, and was previously Vice Chairman of MBIA Insurance Corp., and Founder and CEO of CapMac Holdings. He received his MBA from the UC Berkeley Haas Business School, where he has also served as Adjunct Professor in entrepreneurship.
Peter Espig
Mr. Espig is the CEO of Nicola Mining Inc. (TSX.V: NIM) and Sweet Earth Holdings (CSE: SE). He sits on the board of several public and private companies, as well as charitable organizations. Mr. Espig was a pioneer of special acquisition companies (SPACs) having completed two of the early mega transactions. He was previously Vice President of the Special Situations Group of Goldman Sachs Japan, and Vice President of Olympus Capital, a New York private equity firm. He holds a BA from the University of British Columbia, where he was a member of its National Champion football team, and an MBA from Columbia Business School, where he was an International Chazen Society Fellow.
Rosita Gaw Leong, MD
Dr. Leong is chief executive and director of Bunker Hill Developments, Inc., and of Persis Corporation, both real estate development companies. She is a Trustee of the University of Hawai’i Foundation, and former Chief Pathologist of the Metropolitan Hospital in Manila, Philippines.
Sebastian Guth, PhD
Sebastian Guth is a multi-national executive with 20+ years of experience in pharmaceuticals and medical technology across three continents, with proven results in both strategic and operational leadership roles at the most senior level. Since 2018, he has served as President of Bayer’s Pharmaceuticals business in the Americas Region, comprising the US, Canada, and Latin America. Prior to that, Dr. Guth served as the Executive Vice President and Chief Marketing Officer of Bayer’s global pharmaceuticals, responsible for Xarelto® and Eylea® among other products, and was previously Chief Executive Officer of Bayer Turk, Istanbul and President & CEO of Bayer Yakuhin, Osaka.
He is currently a member of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), and of Children’s Aid. He holds an MBA from the WHU Otto Beisheim Graduate School of Management and a PhD in Management Sciences from Berlin University of Technology in Germany.
Matthew R. Price
Mr. Price is a co-founder of Phosplatin Therapeutics and serves as Executive Vice President and Chief Operating Officer. In addition, he represents one of the founding investors, Absaroka Partners LLC.
Charles E. Stuckey
Mr. Stuckey is Chairman Emeritus and former CEO of RSA Security, which was acquired by EMC Corp in 2006. He also served as a Director of Matrix One until its acquisition in 2006 by Dassault Systems. He is Chairman Emeritus of the Ohio University and Ohio University Foundation Board of Trustees.
Neil V. Sunderland
Dr. Sunderland is Chairman of Adinvest AG, a Swiss family office. He has extensive experience in private equity investments, including the digital economy and the life sciences. Dr. Sunderland has served on the boards of numerous public and private companies including Leica plc, Saurer AG and Xing AG, the leading professional networking platform in the German speaking world that he chaired for many years. He was previously executive director of Swiss Bank Corporation Intl in London and CEO of Elders Finance and Investment Co. in Australia. Dr. Sunderland holds a BSc and MSc from Imperial College, London, and a doctorate from the Swiss Federal Institute of Technology (ETH).
Elizabeth Tallett
Ms. Tallett has more than 35 years of experience across strategic leadership and operational roles in worldwide biopharmaceutical companies. She was Principal of Hunter Partners, which advised Phosplatin Therapeutics early in its development. Previously, she served as President and CEO of Transcell Technologies Inc., and as President of Centocor Pharmaceuticals, which was acquired by Johnson and Johnson in 1999. Earlier in her career she was a member of the executive committee of Parke-Davis. In addition to serving on the Phosplatin Board of Directors, Ms. Tallett currently serves on the boards of Moderna Inc., Anthem, Inc., Qiagen, Inc., and Meredith Corp.
Development Collaborators
-
Martin A. Graham, PhD
PHARMACOKINETICS
Dr. Graham has been involved in drug development for over 25 years and is a specialist in PK /PD analysis, and serves as Lead Pharmacokineticist for Phosplatin Therapeutics' drug development efforts. He began his career at Sanofi-Synthelabo, in both the UK and the US. Dr. Graham later served as Director of Pharmacokinetics at Centocor Corporation, a Johnson and Johnson Company; VP of Research and Development at Gemin X Biotechnologies; and VP of Development and Regulatory Affairs at Tetralogic Pharmaceuticals.
He founded PKPD Bioscience in 2004, which was later integrated into Kinderpharm, a pediatric drug development company he had also founded in 2014. Dr. Graham serves as President & CEO of both entities. With his extensive R&D experience with both small molecules and protein therapeutics from IND to NDA/BLA, Dr. Graham has been involved in numerous regulatory filings in the US, Japan and Europe for a wide variety of products including Oxaliplatin, Rasburicase, Mitoguazone, Tirapazamine, Alfuzosin, Birinapant, Stelara and Remicade.
He is a graduate of Leeds University, England where he earned his BSc in Pharmacology and Microbiology, and went on to earn his PhD from the University of London at the Institute of Cancer Research, Royal Marsden Hospital in 1990. He is the author of a text book on the pharmacokinetics of cancer chemotherapy and has substantial publication record in the area of pharmacokinetics, drug metabolism and clinical pharmacology.
-
Michael H. Silverman, MD, FACP
CLINICAL DEVELOPMENT
Dr. Silverman is a board-certified internist with over 25 years of experience in biopharmaceutical industry clinical research, product development, and strategic planning. He has served Phosplatin Therapeutics in its clinical development matters since inception. His pharmaceutical industry career has included positions of increasing responsibility at both global and start-up companies, where he has managed multiple pharmaceutical and biotechnology projects across a broad scope of therapeutic areas. He is currently President of Biostrategics Consulting, Ltd.
Prior to beginning his consulting activities, among other roles Dr. Silverman served as manager, KPMG Healthcare Consulting; Vice President of Clinical Research at Biopure Corporation in Cambridge, MA; and director of clinical research at Sandoz Research Institute in East Hanover, NJ. He was in clinical practice of medicine for seven years. Dr. Silverman received his BS from the University of Illinois and his MD from the University of Chicago.
-
Thomas Eckrich, PhD
CMC REGULATORY AFFAIRS
Dr. Eckrich is an experienced Chemistry Manufacturing and Controls (CMC) executive with 33 years of experience in the pharmaceutical industry, primarily with Eli Lilly and Company. His accomplishments include NDA submissions for Loracarbef, Gemcitabine, Raloxifene and Tadalafil. He also managed Eli Lilly’s European development center in Mont Saint Guibert, Belgium, leading the growth of the premier small molecule process R&D group in the US pharma industry during the early 2000s, and established a network of more than 30 company relationships for Lilly’s development outsourcing capability.
In 2014, Dr. Eckrich founded Eckrich consulting services, LLC, which provides expertise to the chemical and pharmaceutical industries in chemical process development and manufacturing, with a focus on synthetic organic chemistry. Dr. Eckrich earned a doctorate in Chemistry from Harvard University in 1984, studying with Professor E. J. Corey, the 1990 Nobel Laureate in Chemistry.
Scientific Advisory Board
-
Daniel D. Von Hoff, MD FACP
Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and Medical Director of Research at McKesson Specialty Health, US Oncology Research. He is also Professor of Medicine, Mayo Clinic Scottsdale, AZ.Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.
Dr. Von Hoff has published more than 675 papers, 140 book chapters and over 1170 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was also a Founder of Ilex Oncology, which obtained FDA approval for two new anti-cancer agents: Campath for the treatment of patients with CLL and multiple sclerosis; and Clofarabine for the treatment of children with Leukemia. The company was acquired by Genzyme.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
-
Daniel D. Karp, MD
Dr. Karp graduated from Harvard College in 1969, and received his medical degree from the Duke University School of Medicine in 1973. He was awarded numerous postgraduate and clinical fellowships, including at the Sidney Farber Cancer Institute in Boston from 1978-80. Dr. Karp’s focus at MD Anderson Cancer Center is on new drug development in the phase I facility, as well as medical graphics and informatics, and cancer chemoprevention.Dr. Karp is proud to have had a role in the early clinical trials of Epirubicin, the Taxanes, and the new Targeted Oral Inhibitors of the Epidermal and Vascular Growth Factor Receptors, as well as in recent studies of the Insulin Growth Factor Receptor (IGFR).
-
J. Kay Noel, PhD
Dr. Noel has had thirty years of experience in pharmaceutical drug development. She currently serves as Chief Operating Officer of Collaborative Medicinal Development, a privately held drug development group focused on neuro-degenerative diseases. She was previously Co-founder and COO of OncoEthix SA, which was sold to Merck in 2014, and before that was Co-Founder and VP of Business Development of Oncology Therapeutics Network, which was sold to Bristol Myers Squibb.Earlier in her career she was director of Biologics R&D at Abbott. Dr. Noel holds a PhD in Biophysics from the University of Michigan, and completed post-doctoral studies at UCLA under a fellowship from the National Institutes of Health.
-
Jose Jimeno, MD, PhD
Dr. Jimeno is a seasoned medical oncologist, who also holds a PhD from the University of Barcelona. He has had a focus in drug development for over twenty years. Dr. Jimeno served as Chief Medical Officer at Phosplatin Therapeutics, in which role he was instrumental in the early clinical development of PT-112, and joins the Scientific Advisory Board in order to maintain his involvement in the program. He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for the integrated development of Yondelis®, which is approved in the US, the EU, Japan, and more than 60 other countries for the treatment of ovarian cancer and sarcoma; the development of Aplidine® in advanced cancer patients; and the design of the pivotal study in multiple myeloma, which has had its first approval in Australia.His prior industry roles include work at Farmitalia Carlo Erba and US Biosciences, where he focused on novel compounds in the anthracycline and anti-metabolite therapeutic classes. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company focused on personalized medicine, where he was involved in the development of the EGFR mutation diagnostic approved by the FDA for use in non-small cell lung cancer (NSCLC) cancer patients. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.
-
Lucas A. de Breed, PhD
Dr. Lucas de Breed is the Founder and Managing Director of August Care (AUGC), a tech-enabled financial services company focused on effective market adoption of high-cost precision medicine.Dr. de Breed has over a decade of international experience in all phases of drug development and commercialization and a strong financial background. Previously as a Manager at Deallus, a global strategy consulting firm for Top 30 Pharma clients, he led the oncology business unit and founded the firm’s East Coast office. As an Investment Director at INKEF Capital, a leading European VC firm, he invested $60 million in US and European therapeutics start-ups in the fields of oncology, audiology, fibrosis, neuromuscular disorders, metabolic diseases, and monogenetic rare diseases, and served on the respective Boards. At INKEF, he was involved in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million.
Dr. de Breed holds a PhD from University College London and an MBA from Stanford University. He has also co-authored several scientific papers. He is a director at Quantum Leap Healthcare, and also serves on the Advisory Board of FIRST, an early stage investment fund for cardiovascular and regenerative medicine
Board of Directors
-
Robert E. Fallon, Chairman
Mr. Fallon is Chairman of the Board of Directors. He is a co-founder of Phosplatin Therapeutics and serves as President & CEO. -
John B. Caouette, Vice Chairman
Mr. Caouette is Founding Chairman of Channel Capital, which provides technology-enabled financing to corporates operating in global markets, and was previously Vice Chairman of MBIA Insurance Corp., and Founder and CEO of CapMac Holdings. He received his MBA from the UC Berkeley Haas Business School, where he has also served as Adjunct Professor in entrepreneurship. -
Peter Espig
Mr. Espig is the CEO of Nicola Mining Inc. (TSX.V: NIM) and Sweet Earth Holdings (CSE: SE). He sits on the board of several public and private companies, as well as charitable organizations. Mr. Espig was a pioneer of special acquisition companies (SPACs) having completed two of the early mega transactions. He was previously Vice President of the Special Situations Group of Goldman Sachs Japan, and Vice President of Olympus Capital, a New York private equity firm. He holds a BA from the University of British Columbia, where he was a member of its National Champion football team, and an MBA from Columbia Business School, where he was an International Chazen Society Fellow. -
Rosita Gaw Leong, MD
Dr. Leong is chief executive and director of Bunker Hill Developments, Inc., and of Persis Corporation, both real estate development companies. She is a Trustee of the University of Hawai’i Foundation, and former Chief Pathologist of the Metropolitan Hospital in Manila, Philippines. -
Sebastian Guth, PhD
Sebastian Guth is a multi-national executive with 20+ years of experience in pharmaceuticals and medical technology across three continents, with proven results in both strategic and operational leadership roles at the most senior level. Since 2018, he has served as President of Bayer’s Pharmaceuticals business in the Americas Region, comprising the US, Canada, and Latin America. Prior to that, Dr. Guth served as the Executive Vice President and Chief Marketing Officer of Bayer’s global pharmaceuticals, responsible for Xarelto® and Eylea® among other products, and was previously Chief Executive Officer of Bayer Turk, Istanbul and President & CEO of Bayer Yakuhin, Osaka.He is currently a member of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), and of Children’s Aid. He holds an MBA from the WHU Otto Beisheim Graduate School of Management and a PhD in Management Sciences from Berlin University of Technology in Germany.
-
Matthew R. Price
Mr. Price is a co-founder of Phosplatin Therapeutics and serves as Executive Vice President and Chief Operating Officer. In addition, he represents one of the founding investors, Absaroka Partners LLC. -
Charles E. Stuckey
Mr. Stuckey is Chairman Emeritus and former CEO of RSA Security, which was acquired by EMC Corp in 2006. He also served as a Director of Matrix One until its acquisition in 2006 by Dassault Systems. He is Chairman Emeritus of the Ohio University and Ohio University Foundation Board of Trustees. -
Neil V. Sunderland
Dr. Sunderland is Chairman of Adinvest AG, a Swiss family office. He has extensive experience in private equity investments, including the digital economy and the life sciences. Dr. Sunderland has served on the boards of numerous public and private companies including Leica plc, Saurer AG and Xing AG, the leading professional networking platform in the German speaking world that he chaired for many years. He was previously executive director of Swiss Bank Corporation Intl in London and CEO of Elders Finance and Investment Co. in Australia. Dr. Sunderland holds a BSc and MSc from Imperial College, London, and a doctorate from the Swiss Federal Institute of Technology (ETH). -
Elizabeth Tallett
Ms. Tallett has more than 35 years of experience across strategic leadership and operational roles in worldwide biopharmaceutical companies. She was Principal of Hunter Partners, which advised Phosplatin Therapeutics early in its development. Previously, she served as President and CEO of Transcell Technologies Inc., and as President of Centocor Pharmaceuticals, which was acquired by Johnson and Johnson in 1999. Earlier in her career she was a member of the executive committee of Parke-Davis. In addition to serving on the Phosplatin Board of Directors, Ms. Tallett currently serves on the boards of Moderna Inc., Anthem, Inc., Qiagen, Inc., and Meredith Corp.